David Hallal - 10 Apr 2025 Form 4 Insider Report for Kalaris Therapeutics, Inc. (KLRS)

Role
Director
Signature
/s/ Brett Hagen, Attorney-in-Fact
Issuer symbol
KLRS
Transactions as of
10 Apr 2025
Transactions value $
$0
Form type
4
Filing time
11 Apr 2025, 16:41:02 UTC
Previous filing
01 Jul 2024
Next filing
29 Apr 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KLRS Stock Option (Right to Buy) Award $0 +18,000 $0 18,000 10 Apr 2025 Common Stock 18,000 $7.31 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service.